Cyclophosphamide trials for Triple Negative Breast Cancer

All Cyclophosphamide trials · All Triple Negative Breast Cancer trials

Phase breakdown

Recruiting trials studying Cyclophosphamide for Triple Negative Breast Cancer

• Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
  NCT04437160 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
  NCT05296564 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
  NCT07297667 · Phase: Phase 1 · Ages: 15 Years and older · Sex: All (male and female) · 2 locations
• MicroRNA Profiles in Triple Negative Breast Cancer
  NCT04771871 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations
• Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
  NCT06318897 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
  NCT06245889 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
  NCT05492682 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
  NCT06347068 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
  NCT04282044 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
  NCT05447702 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
  NCT06291064 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations

Common questions

How many trials study Cyclophosphamide for Triple Negative Breast Cancer?

11 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.